Corbus Pharmaceuticals Holdings, Inc.

NASDAQ:CRBP

Biotechnology

Healthcare
$2.75 +1.73%

+$0.14 today

Market cap
$56.57M
Beta
2.59
P/E (TTM)
-1.3
EPS (TTM)
-$6.35
52W Low $6.72High $20.56

Volume 0.63M

Average 0.42M

CRBP Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Corbus Pharmaceuticals Holdings, Inc.NASDAQ: CRBP

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares of 13.32M shares rose 9.1% year over year, behind the +30.5% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +47.3% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +9.1% toward the trailing-twelve-month pace of +30.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
13.32M+0.0% QoQ
Last fiscal yearDec 2025
13.32M+22.0% YoY
LTMMar 2026
12.8M+30.5% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+9.1%——
1 year+22.0%——
3-year CAGR+47.3%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
13.32M USD
Year-over-year change
+22.0%
4-year CAGR
+34.3%

Weighted Avg Shares vs competitors

How CRBP compares with its peers on the latest reported figures

  • CRBP's LTM Mar 2026 weighted avg shares of 12.8M shares is the lowest of the 10 companies compared; the peer median is 86.73M shares.
  • Its year-over-year change of +30.5% is the 6th highest of 10, against a peer median of +32.5%.
  • Over three fiscal years its annual growth of +47.3% compares with a peer median of +25.5%.
CRBP Competitors Peer median
Weighted Avg Shares for CRBP and competitors
Company Period LTM YoY 3-year CAGR
ALECAlector, Inc.LTM Mar 2026104.14M +6.5%+7.7%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026100.04M +230.0%+40.6%
IPHAInnate Pharma S.A.FY202589.42M +10.3%+4.0%
FBRXForte Biosciences, Inc.LTM Mar 202688.77M +1552.7%+496.0%
MISTMilestone Pharmaceuticals Inc.LTM Mar 202686.73M +33.0%+25.5%
CRDFCardiff Oncology, Inc.LTM Mar 202667.15M +30.5%+15.3%
PEPGPepGen Inc.LTM Mar 202644.2M +35.7%+39.2%
MOLNMolecular Partners AGLTM Mar 202637.43M +9.0%+4.7%
ELTXElicio Therapeutics, Inc.LTM Mar 202616.57M +32.5%+70.3%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 202612.8M +30.5%+47.3%
Peer median (excluding CRBP) 86.73M+32.5%+25.5%

Competitors are the stored peer set for CRBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue881.71K0000
Cost of Revenue1.64M1.49M0600K0
Gross Profit(757.53K)(1.49M)0(600K)0
Gross Margin-85.9%————
Research & Development36.45M16.14M31.17M32.22M70.1M
Selling, General & Admin20.43M18.7M13.91M16.5M15.22M
Operating Expenses55.23M33.35M45.08M48.12M85.31M
Depreciation & Amortization1.64M1.49M641K600K233K
EBITDA(42.17M)(38.73M)(40.11M)(37.74M)(78.3M)
EBITDA Margin-4782.9%————
Operating Income(55.99M)(34.84M)(45.08M)(48.72M)(85.31M)
Operating Margin-6350.1%————
Interest Income0006.31M5.53M
Interest Expense1.83M2.13M2.92M1.87M0
Other Income / Expenses10.35M(7.51M)474K8.51M6.77M
Income Before Tax(45.64M)(42.35M)(44.6M)(40.21M)(78.54M)
Pre-Tax Margin-5176.4%————
Income Tax Expense00000
Net Income(45.55M)(55.83M)(44.6M)(40.21M)(78.54M)
Net Margin-5166.4%————
EPS (Basic)(11.13)(10.15)(10.31)(3.68)(5.90)
EPS (Diluted)(11.13)(10.15)(10.31)(3.68)(5.90)
Weighted Avg Shares4.1M4.17M4.33M10.92M13.32M
Weighted Avg Shares (Diluted)4.1M4.17M4.33M10.92M13.32M

Corbus Pharmaceuticals Holdings, Inc.

NASDAQ:CRBP

Intrinsic Alpha fair value

Locked

Current Price

$2.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.